Capvizr

Valo Health Raises $300 million Series B

Company profile · Healthcare & Life Sciences · Updated January 1, 2022

Valo Health raised $300M in Series B financing led by Various. AI multi-modal drug discovery and development platform. The new capital is framed around Advance 4 clinical programs and expand data partnerships with health systems.

Series B$300 millionTotal tracked $300 millionBoston, MA

What it does

AI multi-modal drug discovery and development platform. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.

Traction

AI integrates genomics, imaging, and EHR data to identify novel drug targets. Management framed the new capital around Advance 4 clinical programs and expand data partnerships with health systems.

Trend impact

AI drug discovery using patient data competing with Recursion. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.

Funding history

  • January 1, 2022 · Series B · $300 million · Various

Products & services

  • Healthcare & Life Sciences workflow monitoring tied to the funding announcement
  • Customer-facing product described on the company website
  • Operational tooling for healthcare & life sciences teams
  • Data capture and reporting across core business processes
  • Team expansion support funded by the latest round
Open Valo Health in the interactive Capvizr dashboard →